>
>
Biomarker Research

Biomarker Research

BIOMARK RES
影响因子：11.5
是否综述期刊：否
是否预警：不在预警名单内
是否OA：是
出版国家/地区：ENGLAND
出版社：BioMed Central
发刊时间：2013
发刊频率：
收录数据库：SCIE/Scopus收录/DOAJ开放期刊
ISSN：2050-7771

期刊介绍

Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines.The study of biomarkers has evolved rapidly in the advance of personalized medicine and individual health. The identification and validation of biomarkers in drug discovery/development and in disease diagnosis, treatment, prognosis, and prevention play an essential role in the genome era. With a quick turnaround time from submission to publication and online feedback from readers, Biomarker Research strives to provide fast dissemination of novel findings and new knowledge.
《生物标志物研究》是一本开放获取、同行评审的期刊，涵盖了生物标志物研究的所有方面。Biomarker Research旨在发表生物医学各学科生物标志物研究相关的原创性发现、新概念、评论和综述，生物标志物的研究随着个体化医疗和个体健康的推进而迅速发展。在基因组时代，生物标志物的鉴定和验证在药物发现/开发以及疾病诊断、治疗、预后和预防中发挥着重要作用。从提交到出版的周转时间和读者的在线反馈都很短，Biomarker Research努力提供新发现和新知识的快速传播。
年发文量 125
国人发稿量 83.34
国人发文占比 0.67%
自引率 -
平均录取率-
平均审稿周期 10 Weeks
版面费 -
偏重研究方向 Biochemistry, Genetics and Molecular Biology-Molecular Medicine
期刊官网 https://www.springer.com/journal/40364
投稿链接 https://www.editorialmanager.com/BMRE

期刊高被引文献

Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0159-x
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0173-z
Epigenetic heterogeneity in cancer
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0174-y
Novel insights into MSC-EVs therapy for immune diseases
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0156-0
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0170-2
Mesothelin as a biomarker for targeted therapy
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0169-8
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0160-4
Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0168-9
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0175-x
The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0155-1
Cancer biomarkers for targeted therapy
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0178-7
Targeted therapies for myeloproliferative neoplasms
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0166-y
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0177-8
Evaluation of breast stiffness measured by ultrasound and breast density measured by MRI using a prone-supine deformation model
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0171-1
Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0179-6
Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0167-x
Longitudinal study of leukocyte DNA methylation and biomarkers for cancer risk in older adults
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0161-3
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0154-2
The association between early neurological deterioration and whole blood purine concentration during acute stroke
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0158-y
Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0157-z
Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0162-2
Clinical significance of stromal ER and PR expression in periampullary adenocarcinoma
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0176-9
Identification of TCR Vβ11-2-Dβ1-Jβ1-1 T cell clone specific for WT1 peptides using high-throughput TCRβ gene sequencing
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0163-1
DLGAP1 directs megakaryocytic growth and differentiation in an MPL dependent manner in hematopoietic cells
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0165-z
Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0172-0
A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab
来源期刊：Biomarker ResearchDOI：10.1186/s40364-019-0164-0

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
36.80%100%--

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

查看说明
时间 预警情况
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
*来源：中科院《 国际期刊预警名单》

JCR分区

WOS分区等级：Q1区
版本 按学科 分区
WOS期刊SCI分区
WOS期刊SCI分区
WOS期刊SCI分区是指SCI官方（Web of Science）为每个学科内的期刊按照IF数值排 序，将期刊按照四等分的方法划分的Q1-Q4等级，Q1代表质量最高，即常说的1区期刊。
（2024-2025年最新版）
MEDICINE, RESEARCH & EXPERIMENTAL
Q1

中科院分区

查看说明
版本 大类学科 小类学科 Top期刊 综述期刊
2025年3月最新升级版
医学2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
2区
ONCOLOGY 肿瘤学
2区
否
否
2023年12月升级版
医学2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
2区
ONCOLOGY 肿瘤学
2区
否
否
2022年12月旧的升级版
医学2区
MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验
2区
ONCOLOGY 肿瘤学
3区
否
否